scholarly journals VESS06. Clinical Outcome of Ultrasound-Accelerated Catheter-Directed Thrombolytic Therapy for the Treatment of Submassive Pulmonary Embolism

2017 ◽  
Vol 65 (6) ◽  
pp. 6S-7S ◽  
Author(s):  
Peter Lin ◽  
Elias Kfoury ◽  
Angela Echeverria ◽  
Stanley Duchman ◽  
Joseph Varon ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Clinical Outcome ◽  
Thrombolytic Therapy ◽  
Submassive Pulmonary Embolism

scholarly journals Short-Term Mortality in Patients with Massive and Submassive Pulmonary Embolism Receiving Thrombolytic Therapy

2013 ◽  
Vol 84 (1) ◽  
pp. 62 ◽  
Author(s):  
Yun-Ju Cho ◽  
So-My Koo ◽  
Duk Won Bang ◽  
Ki-Up Kim ◽  
Soo-taek Uh ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Short Term ◽  
Submassive Pulmonary Embolism ◽  
Short Term Mortality

Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?

2016 ◽  
Vol 83 (12) ◽  
pp. 923-932
Author(s):  
Ali Ataya ◽  
Jessica Cope ◽  
Abbas Shahmohammadi ◽  
Hassan Alnuaimat
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Submassive Pulmonary Embolism

scholarly journals Thrombolytic therapy for pulmonary embolism: lessons from recent clinical trials

2015 ◽  
Vol 3 (4) ◽  
Author(s):  
Lexin Wang
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Clinical Studies ◽  
Massive Pulmonary Embolism ◽  
Common Disease ◽  
Thrombolytic Treatment ◽  
Normal Blood Pressure ◽  
Life Saving ◽  
Submassive Pulmonary Embolism

Pulmonary embolism is a common disease that is associated with significant mobility and mortality. Thrombolysis is potentially life saving when used in conjunction with anticoagulant therapy. Indications for thrombolysis for pulmonary embolism are not well defined. In patients with acute massive pulmonary embolism and hypotension, thrombolytic therapy offers some benefits in terms of mortality reduction. The use of thrombolysis in patients with stable haemodynamics has been controversial for more than two decades. Recent clinical studies have indicated that thrombolytic treatment in conjunction with heparin in patients with submassive pulmonary embolism and normal blood pressure can prevent deterioration of the disease and diminish the need for more intensive therapies during hospitalisation. The role of prehospital thrombolytic therapy for acute pulmonary embolism is unclear and further clinical studies are warranted.

Thrombolytic Therapy for Submassive Pulmonary Embolism?

2007 ◽  
Vol 50 (1) ◽  
pp. 78-84 ◽  
Author(s):  
Andrew Worster ◽  
Camala Smith ◽  
Shawna Silver ◽  
Michael D. Brown
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Submassive Pulmonary Embolism

scholarly journals Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism

2018 ◽  
Vol 33 (1) ◽  
pp. 74-89 ◽  
Author(s):  
Lauren A. Igneri ◽  
John M. Hammer
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
English Language ◽  
Right Ventricular Dysfunction ◽  
Hemodynamic Instability ◽  
Minor Bleeding ◽  
Increased Risk ◽  
Submassive Pulmonary Embolism ◽  
Systemic Thrombolytic Therapy

Objective: To critically evaluate the published literature assessing the safety and efficacy of thrombolytic therapy for massive and submassive pulmonary embolism (PE). Methods: A search of human trials in the English-language (September 2017) was conducted through the MEDLINE database using the following terms: PE, tissue plasminogen activator, tenecteplase, and alteplase. 67 unique articles were identified, of which 24 clinical trials discussing clinical outcomes related to administration of either intravenous tenecteplase or alteplase were included. Results: Thrombolytic therapy with anticoagulation significantly reduced mortality compared to anticoagulation alone in massive PE. In submassive PE, thrombolytics reduced the rate of right ventricular dysfunction and hemodynamic collapse; however, there is an increased risk of major and minor bleeding with no benefit on long-term functional outcomes. Conclusions: Patients with massive PE should receive thrombolytics when no major contraindications to therapy exist. Patients with submassive PE at highest risk for progression to hemodynamic instability should receive anticoagulation and be monitored for clinical deterioration. If an imminent risk of hemodynamic instability or cardiac arrest occurs, thrombolytics should be administered if no contraindications exist. Net mortality benefit and risk of bleeding must be considered when deciding to administer thrombolytic therapy in massive or submassive PE.

Sign in / Sign up

Export Citation Format

Share Document